Supplemental Table 1 Summary of clinical parameters

Parameters	Base case value	PSA		Reference
		Distribution	Alpha-Beta	
Initial probabilities				
mRS 0-2 after Alteplase and EVT	0.46	Dirichlet	244-281	4
mRS 3-5 after Alteplase and EVT	0.40	Dirichlet	209-316	4
mRS 6 after Alteplase and EVT	0.14	Dirichlet	72-453	4
mRS 0-2 after Alteplase	0.27	Dirichlet	153-412	4
mRS 3-5 after Alteplase	0.55	Dirichlet	308-257	4
mRS 6 after Alteplase	0.18	Dirichlet	104-461	4
mRS 0-2 after EVT	0.44	Dirichlet	47-61	4
mRS 3-5 after EVT	0.33	Dirichlet	36-72	4
mRS 6 after EVT	0.23	Dirichlet	25-83	4
mRS 0-2 after supportive care	0.22	Dirichlet	18-62	4
mRS 3-5 after supportive care	0.55	Dirichlet	44-36	4
mRS 6 after supportive care	0.23	Dirichlet	18-62	4
Transition probabilities (cycle length is 3 months)				
Movement from 'Independent' to …, up to end of the first year				
Independent	0.955	Dirichlet	1337-63	13, 14
Disability	0.024	Dirichlet	34-1366	13, 14
Recurrent stroke	0.013	Dirichlet	18-1382	13, 14
Dead	0.008	Dirichlet	11-1389	13, 14

1

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Parameters	Base case value	PSA		Reference
		Distribution	Alpha-Beta	
Movement from 'Disability' to …, up to end of the first year				
Disability	0.919	Dirichlet	1287-113	13, 14
Independent	0.029	Dirichlet	41-1359	13, 14
Recurrent stroke	0.013	Dirichlet	18-1382	13, 14
Dead	0.039	Dirichlet	55-1345	13, 14
Movement from 'Recurrent stroke' to …, up to end of the first year				
mRS 0-2 after Alteplase and EVT	0.46	Dirichlet	460-540	14
mRS 3-5 after Alteplase and EVT	0.39	Dirichlet	390-610	14
mRS 6 after Alteplase and EVT	0.15	Dirichlet	150-850	14
mRS 0-2 after Alteplase	0.26	Dirichlet	260-740	14
mRS 3-5 after Alteplase	0.55	Dirichlet	550-450	14
mRS 6 after Alteplase	0.19	Dirichlet	190-810	14
Movement from 'Independent' to …, after the first year				
Independent	0.979	Dirichlet	1371-28	13, 14
Disability	0	Dirichlet	17-1382	13, 14
Recurrent stroke	0.013	Dirichlet	11-1388	13, 14
Dead	0.008	Dirichlet	11-1388	13, 14
Movement from 'Disability' to …, after the first year				

Parameters	Base case value	PSA		Reference
		Distribution	**Alpha-Beta**	
Disability	0.948	Dirichlet	1327-72	13, 14
Independent	0	Dirichlet	17-1382	13, 14
Recurrent stroke	0.013	Dirichlet	54-1345	13, 14
Dead	0.039	Dirichlet	55-1345	13, 14
Movement from 'Recurrent stroke' to …, after the first year				
mRS 0-2 after Alteplase and EVT	0.867	Dirichlet	867-132	14, 15
mRS 3-5 after Alteplase and EVT	0.104	Dirichlet	103-896	14, 15
mRS 6 after Alteplase and EVT	0.029	Dirichlet	28-971	14, 15
mRS 0-2 after Alteplase	0.834	Dirichlet	834-165	14, 15
mRS 3-5 after Alteplase	0.137	Dirichlet	136-863	14, 15
mRS 6 after Alteplase	0.029	Dirichlet	28-971	14, 15
EVT, endovascular treatment; mRS, modified Rankin Scale; PSA, probabilistic sensitivity analysis				

Supplemental Table 2 Summary of cost and utility data

	Base case value (THB)	Univariate sensitivity analysis	PSA		Reference
			Distribution	SE	
Alteplase	50,000	40,000-60,000	NA	NA	NHSO
Thrombectomy devices*	73,800	59,100-114,300	NA	NA	Manufacturers
Treatment costs (3 months cost)					
Acute ischemic stroke (per admission)	97,400	80,000-114,800	Gamma	8,880	Analysis of primary data
Recurrent stroke hospitalization (per admission)	53,500	45,000-62,100	Gamma	4,380	17
Posthospitalization, mRS 0–2	9,360	7,800-10,900	Gamma	790	Analysis of primary data
Posthospitalization, mRS 3-5	9,200	7,600-10,700	Gamma	780	Analysis of primary data
Direct non-medical costs (3 months cost)					
Patient treated with Alteplase and EVT	23,200	21,800-24,600	Gamma	730	Analysis of primary data
Patient treated with Alteplase	25,300	23,700-26,800	Gamma	790	Analysis of primary data

4

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

	Base case value (THB)	Univariate sensitivity analysis	PSA		Reference
			Distribution	SE	
Patient treated with EVT	26,200	24,500-27,800	Gamma	820	Analysis of primary data
Patient treated with supportive care	28,700	26,900-30,500	Gamma	910	Analysis of primary data
Patients with recurrent stroke	15,400	14,400-16,400	Gamma	500	17, 18
Posthospitalization (OPD visits), mRS 0–2	12,500	11,700-13,300	Gamma	400	Analysis of primary data
Posthospitalization (OPD visits), mRS 3-5	10,800	10,200-11,500	Gamma	340	Analysis of primary data
Discount rate for cost and outcome	3%	0-4% (cost) 0-2% (outcome)			9
Utility scores					
Independent	0.86	0.82-0.90	Beta	210-34	Analysis of primary data
Disability	-0.23	-0.33-(-0.13)	Beta	51-13	Analysis of primary data
Recurrent stroke	0.34	0.33-0.35	Beta	540-5685	15
Dead	0				

5

	Base case value (THB)	Univariate sensitivity analysis	PSA		Reference
			Distribution	SE	
EVT, endovascular treatment; mRS, modified Rankin Scale; THB, Thai baht; PSA, probabilistic sensitivity analysis; SE, standard error; NHSO, National Health Security Office					
*Includes all equipment for the EVT procedure: catheter, micro guidewire, micro catheter, guidewire, introducer short sheath, guiding catheter and intracranial stent (it is assumed that only 5% patients require an intracranial stent)					